We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Wholesalers are scrambling to find a strategy to stop the FDA from implementing a drug tracking rule they say will allow a few large companies to monopolize the market, forcing smaller competitors out of business.
Growing economies, continued regulatory activity and increasing openness on the part of Asian governments to communicate with industry are creating “great opportunities” for devicemakers to shape developing Asian markets, according to Carolyn Albertson, director of international regulatory affairs for Abbott Laboratories.
Devicemakers should be aware that clinical trial data is crucial to how the Centers for Medicare & Medicaid Services (CMS) will reimburse device manufacturers after approval, according to experts speaking last month at the annual Regulatory Affairs Professionals Society conference.
IMS Health projections predict a lower growth rate for the global pharmaceutical market in 2007, with the U.S. in particular contributing less due to generic competition and an increase in niche products.
IMS Health projections predict a lower growth rate for the global pharmaceutical market in 2007, with the U.S. in particular contributing less due to generic competition and an increase in niche products.
The growing use of internet advertising benefits smaller pharmaceutical companies that lack the resources to compete using more traditional methods to market their products, industry observers say.
Warner Chilcott is forbidden to enter reverse payment agreements — where brand companies pay generic competitors to delay launching their version of a drug — with generic pharmaceutical companies, under a legal settlement the drugmaker has reached with the FTC.
IMS Health projections predict a lower growth rate for the global pharmaceutical market in 2007, with the U.S. in particular contributing less due to generic competition and an increase in niche products.
Pfizer will seek to cut operating costs amid lower revenue projections for 2007 and 2008, the pharmaceutical giant said in its third quarter financial report.
Eli Lilly developed fraudulent practice guidelines based on limited data, input from researchers with financial conflicts and the work of industry front groups to increase sales of its sepsis treatment Xigris, according to three NIH investigators.